Phase IIb Trial of IRAK4 Inhibitor, PF-06650833, in Patients With Moderately to Severely Active RA and Inadequate Response to MTX

November 8-13, 2019; Atlanta, Georgia
PF-06650833 associated with improvements in SDAI in primary analysis.
Format: Microsoft PowerPoint (.ppt)
File Size: 171 KB
Released: November 18, 2019

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
Gilead Sciences
Mallinckrodt Pharmaceuticals

Related Content

New from EULAR 2020: risk of JAKi, IL-6i, abatacept vs TNFi discontinuation among patients with rheumatoid arthritis, as reported by Clinical Care Options (CCO)

Released: July 1, 2020

From EULAR 2020, new safety analysis of risk for thromboembolic events with tofacitinib and baricitinib in RA, reported by Clinical Care Options (CCO)

Released: July 1, 2020

From EULAR 2020, new data from RABBIT trial assessing risk of herpes zoster infection among RA patients by class of DMARD, as reported by CCO

Released: July 1, 2020

CCO faculty Dr. Jonathan Kay’s viewpoint on data from 2019 ACR/ARP on novel approaches for treatment of RA

Jonathan Kay, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: January 9, 2020 Expired: January 8, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?